EE186 Cost-Utility of Nivolumab Versus Observation for the Adjuvant Treatment of Urothelial Carcinoma (UC) for Patients Who Are at High-Risk of Recurren A United States (US) Payer Perspective
Abstract
Authors
B Rothwell K Sheikh C Knight F Kamgar R Jain R Mamtani M Kurt T Poretta E Broughton S Teitsson